




RealRate

PHARMACEUTICAL 2020

Enveric Biosciences Inc.
Rank 199 of 358





RealRate

PHARMACEUTICAL 2020

Enveric Biosciences Inc. Rank 199 of 358



The relative strengths and weaknesses of Enveric Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enveric Biosciences Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 154% points. The greatest weakness of Enveric Biosciences Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 63%, being 27% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	7,599
Cost of Goods Sold	31,764
Intangible Assets	17,314
Liabilities, Current	14,384
Liabilities, Non-Current	0
Other Assets	8.9
Other Compr. Net Income	-453
Other Expenses	2,654
Other Liabilities	0
Other Net Income	1,110
Other Revenues	39,915
Property and Equipment	83
Research and Development	0
Selling, General and Administrative Expense	12,210

Output Variable	Value in 1000 USD
Assets	25,005
Liabilities	14,384
Expenses	46,628
Revenues	39,915
Stockholders Equity	10,622
Net Income	-5,604
Comprehensive Net Income	-5,830
Economic Capital Ratio	63%